Do you use cabozantinib preferentially over other TKIs in mRCC patients who have progressed on immunotherapy with primary metastatic burden being bony disease?   

Cabozantinib sounds a very good option in that scenario extrapolated from data from the METEOR (but differences in prior therapy) & CABOSUN trials (in different line of therapy). If a patient can tolerate it, it is a very reasonable option.Other VEGF TKIs (e.g. axitinib, sunitinib, pazopanib), l...

It’s clear from several retrospective series that all TKIs have some activity after IO in RCC. Although Cabo’s MET inhibition has hypothesized advantages in bone, the clinical data is unclear. The HR for PFS benefit favored Cabo in bone met patients vs everolimus in METOER but not over Sutent in...